Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Trial Profile

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2019

At a glance

  • Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms NeoPalAna
  • Most Recent Events

    • 02 May 2019 Planned number of patients changed from 55 to 87.
    • 02 May 2019 Planned End Date changed from 30 Apr 2025 to 30 Apr 2027.
    • 02 May 2019 Planned primary completion date changed from 31 Dec 2020 to 30 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top